儿童的B细胞非霍奇金淋巴瘤:与先天免疫错误的高相关性
Nilgün Kurucu1, Tezer Kutluk1, Arzu Sağlam2
1Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
Leukemia & lymphoma
|July 5, 2024
概括
儿科无效淋巴瘤,包括PTFL和PMZL,很少见,但与免疫的先天性错误有关. 用Rituximab或R-CHOP治疗显示儿童的生存率非常好.
科学领域:
- 儿科瘤学 儿科瘤学
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 软性淋巴瘤在儿童中很少见,主要包括儿科类型的毛囊淋巴瘤 (PTFL) 和儿科边缘区域淋巴瘤 (PMZL).
- 在儿科病例中也观察到外节边缘区域淋巴瘤 (ENMZL).
- 这些淋巴瘤仅占儿科非霍奇金淋巴瘤 (NHL) 病例的一小部分.
研究的目的:
- 以回顾评估儿科无痛淋巴瘤的临床特征,治疗和结果.
- 调查免疫系统的先天性错误 (IEI) 和儿科无效淋巴瘤之间的关联.
- 评估基于Rituximab和R-CHOP的化疗方案的疗效.
主要方法:
- 在2000年至2018年期间,对20名被诊断患有无效淋巴瘤 (PTFL,PMZL,ENMZL,混合类型) 的儿童进行了回顾性分析.
- 评估患者的人口统计,临床表现,阶段,治疗方案和生存数据.
- 对IEI患有侵袭性淋巴瘤的统计比较.
主要成果:
- 平均年龄为10.4岁,PTFL患者明显年轻于PMZL患者.
- 观察到与免疫相关的先天性错误 (35%) 的高患病率,明显高于侵略性淋巴瘤.
- 大多数患者 (85%) 呈现出早期 (I/II) 疾病.
- 治疗涉及单独的手术,rituximab或R-CHOP,结果非常出色.
结论:
- 儿科无源性淋巴瘤,特别是PTFL,与显著的先天性免疫错误发生率有关.
- 早期的疾病和有效的治疗方案,包括rituximab和R-CHOP,有助于优秀的预后.
- 需要进一步研究小儿麻木性淋巴瘤的免疫病原发生.
相关概念视频
Immunodeficiency Diseases
933
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
933
Cells of the Adaptive Immune Response
977
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
977
Development of Immunocompetence
300
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
300
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K


